DHODH

Across TCGA pan-cancer cohorts, DHODH mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DHODH data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DHODH mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DHODH expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where DHODH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.705	0.813	.009	13	view →
CCRCC	DFS	Quartile	II,III,IV	0.416	0.800	.007	3	view →
LUAD	OS	Median	All	0.964	0.794	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

DHODH–PDAC (DFS)

Open the PDAC breakdown →